Business

Ventripoint Announces Filing of Articles of Amendment

(TheNewswire) Toronto, Ontario – TheNewswire – Janu...

articleVentripoint Diagnostics Ltd.January 13, 20214/company/ventripoint-diagnostics-ltd/news/ventripoint-announces-filing-of-articles-of-amendment
Ventripoint Announces Filing of Articles of Amendment

About this update from Ventripoint Diagnostics Ltd.

[{"type":"text","content":"Ventripoint Announces Filing of Articles of Amendment\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario – TheNewswire –\nJanuary 13, 2021\n \n \n - Ventripoint Diagnostics Ltd.\n(\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"), (TSXV:VPT\n \n \n )\n \n \n (\n \n \n OTC:VPTDF)\n \n \n announces it has filed articles of amendment in\naccordance with the Canada Business Corporations Act to change the\nprovince in which the registered office of the Company is located from\nAlberta to Ontario. Shareholders of the Company approved the amendment\nat the annual and special meeting of shareholders held on December 14,\n2020.\n \n \n \n \n A copy of the articles of amendment will be posted on\nthe Company’s issuer profile on SEDAR at www.SEDAR.com\n \n \n \n \n About Ventripoint Diagnostics\nLtd.\n \n \n \n \n Ventripoint\n \n \n has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary KBR technology, which is the result of a decade of\ndevelopment and provides accurate volumetric cardiac measurements\nequivalent to MRI. This affordable, gold-standard alternative allows\ncardiologists greater confidence in the management of their patients.\nProviding better care to patients serves as a springboard and basic\nstandard for all of Ventripoint's products that guide our future\ndevelopments. In addition, VMS+ is versatile and can be used with all\nultrasound systems from any vendor supported by regulatory market\napprovals in the U.S., Europe and Canada.\n \n \n \n \n For\n \n \n further information, please\ncontact:\n \n \n \n \n Dr. George Adams\n \n \n \n \n \n [email protected]\n \n \n \n \n \n Tel: 519-\n \n \n 803-6937\n \n \n \n \n Neither the TSX Venture Exchange nor its Regulation\nServices Provider (as that term is defined in the policies of the TSX\nVenture Exchange) accepts responsibility for the adequacy or accuracy\nof this news release.\n \n \n \n Copyright (c) 2021 TheNewswire - All rights reserved.\n \n \n","length":3562,"tagName":"div"}]

More updates from Ventripoint Diagnostics Ltd.